Sana Biotechnology (NASDAQ:SANA) Shares Up 8% – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares shot up 8% during trading on Tuesday . The company traded as high as $2.90 and last traded at $2.9050. 5,943,148 shares changed hands during mid-day trading, an increase of 88% from the average session volume of 3,153,339 shares. The stock had previously closed at $2.69.

Analyst Ratings Changes

Several analysts recently issued reports on SANA shares. Morgan Stanley reiterated an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a research report on Friday, March 13th. Rodman & Renshaw started coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 target price for the company. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Stock Down 1.8%

The business has a 50 day moving average of $3.23 and a 200 day moving average of $3.80. The company has a market capitalization of $770.86 million, a P/E ratio of -2.98 and a beta of 2.14.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, research analysts anticipate that Sana Biotechnology, Inc. will post -0.59 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Sana Biotechnology by 4.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after acquiring an additional 2,023 shares during the last quarter. Xponance LLC lifted its stake in shares of Sana Biotechnology by 25.6% during the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock worth $53,000 after acquiring an additional 2,662 shares during the last quarter. Creative Planning lifted its stake in shares of Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after acquiring an additional 2,719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Sana Biotechnology by 29.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after acquiring an additional 2,943 shares during the last quarter. Finally, Savant Capital LLC lifted its stake in shares of Sana Biotechnology by 5.6% during the 3rd quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after acquiring an additional 3,500 shares during the last quarter. 88.23% of the stock is owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.